SCHEMBL1021152

SCHEMBL1021152

CCCC(CN)Nc1nc(Cc2ccc(OC)cc2)ns1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 5/20 0.39
TAS1R1 Q7RTX1 5/20 0.39
LMNA P02545 3/20 0.39
MAPT P10636 2/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CYP2D6 P10635 2/20 0.36
ALDH1A1 P00352 2/20 0.36
ATM Q13315 1/20 0.36
HTR6 P50406 1/20 0.35
LTA4H P09960 1/20 0.35
DRD1 P21728 1/20 0.35
HTR2A P28223 1/20 0.35
ADORA1 P30542 1/20 0.35
HPGD P15428 1/20 0.34
ADRB2 P07550 2/20 0.34
TLR8 Q9NR97 1/20 0.34
TLR7 Q9NYK1 1/20 0.34
HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1021253 0.91 MAPT (0.40) TAS1R3TAS1R1LMNAMAPTNPC1
SCHEMBL1020608 0.87 TAS1R3 (0.34) TAS1R3TAS1R1LMNAALDH1A1HTR6
SCHEMBL1021148 0.87 NPC1 (0.41) TAS1R3TAS1R1NPC1ALDH1A1HTR6
SCHEMBL1021362 0.86 MAPT (0.39) TAS1R3TAS1R1LMNAMAPTNPC1
SCHEMBL1019377 0.86 ALDH1A1 (0.35) ALDH1A1HTR6TLR8TLR7
SCHEMBL1021292 0.86 NPC1 (0.37) MAPTNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL1020398 0.81 MAPT (0.40) LMNAMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL1021454 0.80 TLR7 (0.39) MAPTALDH1A1ATMHTR6LTA4H
SCHEMBL1021153 0.80 LMNA (0.39) LMNAMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL1020848 0.80 ALDH1A1 (0.38) TAS1R3TAS1R1LMNAMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960556-B2 Thiadiazole derivatives for the treatment of neuro-degenerative diseases NV REMYND (BE) 2011-06-14 US disclosed
EP-2094677-B1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES REMYND NV (BE) 2011-01-12 EP disclosed
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES SNCA, PARK7, PRNP TAS1R3 605/4885TAS1R1 1160/4885LMNA 1913/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.